As of Wednesday close, Creative Medical Technology Holdings Inc.’s (NASDAQ:CELZ) stock was up $0.01, moving up 2.83 percent to $0.40. The average number of shares traded per day over the past five days has been 170,800 shares. 2 times new highs have been achieved over the past 5 days, with a $0.0099 gain in that time frame. In the last twenty days, the average volume was 1,003,715, while in the previous 50 days, it was 533,102.
Since last month, CELZ stock retreated -6.78%. Shares of the company fell to $0.3700 on 11/17/22, the lowest level in the past month. A 52-week high of $6.21 was reached on 03/28/22 after having rallying from a 52-week low of $0.33. Since the beginning of this year, CELZ’s stock price has dropped by -81.90% or -$1.8100, and marked a new high 3 times. However, the stock has declined by -93.56% since its 52-week high.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
CELZ stock investors should be aware that Creative Medical Technology Holdings Inc. (CELZ) stock had its last reported insider trading activity 2 days ago on Nov 22. Warbington Timothy, the President & CEO of the company, purchased of 10,000 shares for $0.39 on Nov 22. It resulted in a $3,897 investment by the insider. Warbington Timothy added 15,000 shares at an average price of $0.40 on Nov 21. The insider now owns 102,087 shares following the transaction. On Sep 27, President & CEO Warbington Timothy bought 20,000 shares at $0.50 apiece. The transaction was valued at $10,000.
The stock’s beta is 4.67. Besides these, the trailing price-to-sales (P/S) ratio of 40.65, the price-to-book (PB) ratio of 0.25.
In the three months ended June 29, Creative Medical Technology Holdings Inc.’s quick ratio stood at 55.40, while its current ratio was 55.40, showing that the company is able to pay off its debt. Based on annual data, CELZ earned $40000.0 in gross profit and brought in $88000.0 in revenue.
CELZ’s revenue rose 83.33% during the quarter, while net income inched up to $60000.0. While analysts expected Creative Medical Technology Holdings Inc. to report -$0.15 quarterly earnings, the actual figure was -$0.2 per share, beating the consensus estimate by -33.30%. During the quarter, the company generated -$1.0 million in EBITDA. The liabilities of Creative Medical Technology Holdings Inc. were 0.4 million at the end of its most recent quarter ended June 29, and its total debt was $14190.0. The value of shareholders’ equity is $14.08 million.
This quick technical analysis looks at Creative Medical Technology Holdings Inc.’s (CELZ) price momentum. With a historical volatility rate of 32.86%, the RSI 9-day stood at 45.97% on 23 November.
With respect to its five-day moving average, the current Creative Medical Technology Holdings Inc. price is up by +2.54% percent or $0.0099. At present, CELZ shares trade -8.82% below its 20-day simple moving average and -46.09% percent below its 100-day simple moving average. However, the stock is currently trading approximately -41.48% below its SMA50 and -76.47% below its SMA200.
Stochastic coefficient K was 11.01% and Stochastic coefficient D was 8.79%, while ATR was 0.0446. Given the Stochastic reading of 21.43% for the 14-day period, the RSI (14) reading has been calculated as 44.58%.
With a median target price of $10.00, the current consensus forecast for the stock is $10.00 – $10.00. Based on these forecasts, analysts predict Creative Medical Technology Holdings Inc. (CELZ) will achieve an average price target of $10.00.